Our online resource featuring the latest news about our company.
RECENT NEWS, BLOGS AND ARTICLES
Press Release |
August 25, 2023
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Read more >
July 11, 2023
EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023
August 23, 2023
Going ‘deep human’ to find the next oncology game changer.
July 10, 2023
Eisai Co., Ltd. announces that Ivan Cheung, Senior Vice President, will leave the Company as of July 31st, 2023
CORPORATE FACT SHEET
Learn more about Eisai Inc.
EXTON FACT SHEET
Learn about our Exton, PA campus
Find digital assets (logos and images) for Eisai
For media inquiries, please contact:
Patricia Councill Director, Corporate Communications 551-262-2686 Patricia_Councill@eisai.com
Libby Holman Senior Director, Product Communications 201-753-1945 Libby_Holman@eisai.com
Michele Randazzo Director, Product Communications 201-248-2228 Michele_Randazzo@eisai.com
For current investors or those interested in becoming investors, please click below to be connected with the global Eisai Investor page.
Stay up to date on everything Eisai.
Find us on
Find us on